Colorectal Cancer Clinical Trials in Atlanta

Showing 41-60 of 283 trials

A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy

NCT06055439

The goal of this clinical trial is to evaluate CHM-2101, an autologous CDH17 CAR T-cell therapy for the treatment of advanced gastrointestinal (GI) cancers that are relapsed or refractory to at least 1 standard treatment regimen in the metastatic or locally advanced setting.

Neuroendocrine TumorsColorectal CancerGastric Cancer

Chimeric Therapeutics135 participantsStarted May 2024

Atlanta, Georgia, United States • Chicago, Illinois, United States • Philadelphia, Pennsylvania, United States +1 more locations

Active Not RecruitingPhase 2/3< 1 mile

Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer

NCT05710406

This phase II/III trial compares treatment with encorafenib and cetuximab to usual care (patient observation) for reducing the chance of cancer recurrence after standard surgery and chemotherapy in patients with BRAF-mutated stage IIB-III colon cancer. Encorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cetuximab is in a class of medications called monoclonal antibodies. It binds to a protein called EGFR, which is found on some types of tumor cells. This may help keep tumor cells from growing. Giving encorafenib and cetuximab after standard surgery and chemotherapy may be more effective at reducing the chance of cancer recurrence compared to the usual patient observation.

Colon AdenocarcinomaMicrosatellite Stable Colon CarcinomaStage IIB Colon Cancer AJCC v8+2 more

Alliance for Clinical Trials in Oncology1 participantsStarted Aug 2023

Millville, Delaware, United States • Newark, Delaware, United States • Newark, Delaware, United States +199 more locations

A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy

Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer

Colorectal Cancer Trials in Other Cities

A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer

A Study of PHN-010 in Patients With Advanced Solid Tumors

Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study

EXoPERT EMERALD Clinical Study

A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.

Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours

Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

Early Onset Colorectal Cancer Detection

Other Conditions in Atlanta